SNMMI 2021 Annual Meeting

Viewing 1-15 of 15 articles

SNMMI 2021: CT and MRI Appearances of Adrenal Lesions

SNMMI 2021: CT and MRI Appearances of Benign and Malignant Lesions in Prostate Cancer

SNMMI 2021: Characterizing Bone Lesions in Prostate Cancer Patients with PET/CT Imaging

SNMMI 2021: A Phase 3 Study of 18F-DCFPyL-PET/CT in Patients With Biochemically Recurrence Prostate Cancer (CONDOR): An Analysis of Disease Detection Rate and Positive Predictive Value by Anatomic Region

SNMMI 2021: PSMA PET Drug Development: Clinical Trial Design and Statistical Considerations

SNMMI 2021: Practical Applications and Clinical Utility of an 18F PSMA-Targeted PET Imaging Agent: Implications for Urology and Radiation Oncology

SNMMI 2021: Metastatic Disease Response and Patterns of Recurrence in Men with High-Risk Prostate Cancer After Neo-Adjuvant Chemohormonal Therapy and Radical Prostatectomy Utilizing PSMA-Targeted 18F-DCFPyL PET/CT

SNMMI 2021: 68Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy

SNMMI 2021: Safety and Efficacy of Radioligand Therapy with 177lutetium-PSMA-617 Within 3 Months After 223Radium-Dichloride

SNMMI 2021: Imaging and Clinical Factors Impacting PSA Response in Patients with Metastatic Castrate Resistant Prostate Cancer Undergoing Lu177-PSMA-617 Therapy

SNMMI 2021: The Phase 3 VISION Trial: Evaluating the Efficacy of 177-Lu-PSMA (LuPSMA) in the Treatment of Patients with PSMA-Positive mCRPC

SNMMI 2021: Osseous Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer (mCRPC)

SNMMI 2021: 225Ac-PSMA-617 Targeted Alpha Therapy in Metastatic Castration Resistant Prostate Cancer Patients

SNMMI 2021: Beta Emitting PSMA Molecular Radiotherapy in mCRPC

SNMMI 2021: Alpha Emitting PSMA Molecular Radiotherapy for mCRPC